Archive for the ‘Commentary’ Category

Mind the patents when growing soybeans or stem cells

Author: Paul Krzyzanowski, 06/06/13

GMO soybeans might have lessons for cell patents. Photo: Philip Dean via Flickr . At first glance, you wouldn’t think that a 76-year old soybean farmer from Indiana would have something in common with microbiologists, but Vernon Hugh Bowman brought back memories of my undergraduate genetics courses and growing E. coli on antibiotic-laden petri dishes….Read more

Women in science: a fairy tale?

Author: Stacey Johnson, 06/04/13

. If you have read any of my previous blogs, you will know that I am not a scientist. From my bio, you will learn that I’m a communications professional, but it doesn’t state that I’m also the mother of two daughters. My almost 10-year-old says she wants to be a scientist when she grows…Read more

Why research? The personal foundations of cancer research

Author: Sara M. Nolte, 05/30/13

. My interest (maybe even fascination) in cancer began when I was six years old: I was diagnosed with acute myeloblastic leukemia (a cancer of white blood cells), and am now able to say that I am a childhood cancer survivor. After realizing that I was no longer interested in going to medical school to…Read more

Rush to publish and the repercussions of carelessness in science

Author: Lisa Willemse, 05/24/13

Co-authored with Dr. Zubin Master, Assistant Professor at the Alden March Bioethics Institute, Albany Medical College and Research Associate at the University of Alberta’s Health Law and Science Policy Group. In the current discussion about the now controversial SCNT human cloning paper by Shoukhrat Mitalipov et al., much has already been said of the reported errors that resulted…Read more

Life and death: The human face of the cell therapy industry

Author: David Brindley, 04/22/13

. Within the past few weeks, we have all lost someone who has impacted our lives. And this I can guarantee. On Monday 8th April 2013, I woke up, grabbed my tennis bag and headed for a morning hit. In the car, I heard the lacquered voice of the BBC’s John Humphrys report the death…Read more

Social media and stem cells: Time to start tweeting

Author: Ben Paylor, 04/03/13

Why should stem cell researchers use Twitter? Powerful news aggregator/information filter Able to engage/converse with other attendees at conferences & meetings Increase traffic, discussion and citations of your papers Create professional networks and opportunities for collaboration  Aid the longevity of stem cell research and pace by which it progresses Research is about discovery. The words…Read more

Clinical trials: a valid or fallacious metric of industry progress?

Author: David Brindley, 03/19/13

. Part 5 in Cell Therapy Industry 2027 series  A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the region’s finest and an American radio show discussing scientific…Read more

BioTime: A new Geron, without a decade of baggage

Author: Paul Krzyzanowski, 03/13/13

Avid watchers of the stem cell and regenerative medicine market have no doubt heard of Geron selling its stem cell assets to BioTime. Nature covered it in some detail last month, and the transaction itself follows a Letter of Intent announced last November, which valued it at approximately $71 million. The transaction leaves Geron to…Read more

Stem cell pseudoscience in the courts?

Author: Ubaka Ogbogu, 02/26/13

Patients contemplating medical travel for the purpose of receiving scientifically unproven stem cell treatments may wish to consider one more potential side effect: the possibility of losing their eligibility for health status-related compensation and benefits. In May 2012, a United States appeal court affirmed an earlier New York district court decision to deny disability and…Read more

State politics and the stem cell policy environment in the United States

Author: Nick Dragojlovic, 02/20/13

- The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is consistent with existing statutes, such as the Dickey-Wicker Amendment. The principal implication of this…Read more